Antibody Type: Rabbit Monoclonal

Application: WB, FCM, ICC/IF, IP

Reactivity: Human

Rabbit IgG

9L104

Human

1. Immunofluorescence staining of Human PARK7 in Hela cells. Cells were fixed with 4% PFA, permeabilzed with 0.3% Triton X-100 in PBS, blocked with 10% serum, and incubated with rabbit anti-Human PARK7 monoclonal antibody (1:60) at 37°C 1 hour. Then cells were stained with the Alexa Fluor® 594-conjugated Goat Anti-rabbit IgG secondary antibody (red) and counterstained with DAPI (blue). Positive staining was localized to cytoplasm.
2. Flow cytometric analysis of Human PARK7 expression on HeLa cells. The cells were treated according to manufacturer’s manual (BD Pharmingen™ Cat. No. 554714), stained with purified anti-Human PARK7, then a FITC-conjugated second step antibody. The fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of intact cells.
3. Anti-PARK7 rabbit monoclonal antibody at 1:1000 dilution.
-Lane A: Hela Whole Cell Lysate.
-Lane B: Jurkat Whole Cell lysate.
-Lysates/proteins at 30 μg per lane.
-Secondary
-Goat Anti-Rabbit IgG H&L (Dylight800) at 1/10000 dilution.
-Developed using the Odyssey technique.
-Performed under reducing conditions.
-Predicted band size:20 kDa.
-Observed band size:24 kDa.
4. PARK7 was immunoprecipitated using:
-Lane A:0.5 mg Jurkat Whole Cell Lysate.
-Lane B:0.5 mg Hela Whole Cell Lysate.
-Lane C:0.5 mg 293T Whole Cell Lysate.
-2 µL anti-PARK7 rabbit monoclonal antibody and 15 μl of 50 % Protein G agarose.
-Primary antibody:
-Anti-PARK7 rabbit monoclonal antibody, at 1:1000 dilution.
-Secondary antibody:
-Dylight 800-labeled antibody to rabbit IgG (H+L), at 1:5000 dilution.
-Developed using the odyssey technique.
-Performed under reducing conditions.
-Predicted band size: 20 kDa.
-Observed band size: 20 kDa

WB,FCM,ICC/IF,IP

WB: 1:1000-1:5000; ICC-IF: 1:20-1:100; FCM: 1:25-1:100; IP: 1-4 μL/mg of lysate

Monoclonal

Unconjugated

Recombinant Protein: Human PARK7 / DJ-1 protein (TMPY-02043)

Human